Effect of XXXX on Bronchial Asthma. III.

@entity1 @entity268 @entity565 @entity1955 @entity230 @entity1954
In two previous communications we demonstrated that @entity1954 (T3) improved cases of chronic @entity565 (CBA). In this communication we administered T3 in a dose of 40 microgram/day for a period of sixty days to twelve cases of CBA aged less than 38 years who had had the condition for more than 5 years and were not on @entity230 or chromoglycate. All were outpatients. Respiratory functions including vital capacity and timed expiratory volume were tested before and after the period of drug administration. @entity1 were also advised to record the number of attacks and amount of bronchodilators used. All @entity1 had their % T3 uptake and @entity1955 (T4) serum level examined before the experiment. Ten normal @entity1 of matching ages and sexes had their blood examined for % T3 uptake and levels as control. The results have shown that the @entity1 had normal % T3 uptake and T4 levels in blood. Their vital capacity increased by an average of 4.27%, their first-second expiratory volume by 17.58% (P less than 0.0025), their second-second expiratory volume by 13.74% (P less than 0.0025%), and their maximal ventilatory volume by 12.95% (P less than 0.0025). Five cases had an increase of over 20% and 5 cases had practically no increase or a mild reduction. Subjective improvement and reduction in amount of bronchodilators used correlated well with the improvement in ventilation. It is argued that T3 acts through having the capacity to increase @entity268 , a main messenger in bronchodilation that is known to be deficient in asthmatics.
